eigerbio.com
The Lancet Publishes Results of Phase 2 Study of Lonafarnib in HDV Infected Patients - EigerBio
http://www.eigerbio.com/the-lancet-infectious-diseases-journal-publishes-results-of-phase-2-study-of-lonafarnib-in-hepatitis-delta-virus-hdv-infected-patients
The Lancet Publishes Results of Phase 2 Study of Lonafarnib in HDV Infected Patients - EigerBio. A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. Click Here to See a Larger Pipeline Graphic. July 12, 2016 at 9am EST. Click Here for Webcast Link. As obesity an...
eigerbio.com
Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for HDV Infection - EigerBio
http://www.eigerbio.com/press-release-2-december-22-2014
Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for HDV Infection - EigerBio. A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. Click Here to See a Larger Pipeline Graphic. July 12, 2016 at 9am EST. As obesity ...
eigerbio.com
Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) - EigerBio
http://www.eigerbio.com/eiger-bio-announces-interim-results-of-lonafarnib-in-combination-with-ritonavir-or-pegylated-interferon-in-patients-infected-with-hepatitis-delta-virus-hdv
Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) - EigerBio. A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. July 12, 2016 at 9am EST. As obesity and...
eigerbio.com
Management Team - EigerBio
http://www.eigerbio.com/about-eiger/management-team
Management Team - EigerBio. A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. Click Here to See a Larger Pipeline Graphic. July 12, 2016 at 9am EST. Click Here for Webcast Link. Click here to view the most recent and past press releases. As obesity and type II...
eigerbio.com
Careers - EigerBio
http://www.eigerbio.com/careers
A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. Click Here to See a Larger Pipeline Graphic. July 12, 2016 at 9am EST. Click Here for Webcast Link. Click here to view the most recent and past press releases. Investor News and Events. LOWR HDV 3 Duration Study.
eigerbio.com
Board of Directors - EigerBio
http://www.eigerbio.com/about-eiger/board-of-directors
Board of Directors - EigerBio. A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. Click Here to See a Larger Pipeline Graphic. July 12, 2016 at 9am EST. Click Here for Webcast Link. Click here to view the most recent and past press releases. As obesity and type...
eigerbio.com
Staff Announcement April 14, 2015 - EigerBio
http://www.eigerbio.com/staff-announcement-april-14-2015
Staff Announcement April 14, 2015 - EigerBio. A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. Click Here to See a Larger Pipeline Graphic. July 12, 2016 at 9am EST. Click Here for Webcast Link. Click here to view the most recent and past press releases.
eigerbio.com
lonafarnib - EigerBio
http://www.eigerbio.com/pipeline/lonafarnib
A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. Click Here to See a Larger Pipeline Graphic. July 12, 2016 at 9am EST. Click Here for Webcast Link. Click here to view the most recent and past press releases. Investor News and Events. LOWR HDV 3 Duration Study.
eigerbio.com
Corporate Overview - EigerBio
http://www.eigerbio.com/about-eiger/corporate-overview
Corporate Overview - EigerBio. A Biopharmaceutical Company Developing a Diverse Portfolio of Well-Characterized Drugs for Orphan Diseases. Eiger BioPharmaceuticals, Inc. 350 Cambridge Ave, Suite 350. Palo Alto, CA 94306. Click Here for Directions. Click each therapeutic area on the pipeline to the right to see more information. Click Here to See a Larger Pipeline Graphic. July 12, 2016 at 9am EST. Click Here for Webcast Link. Click here to view the most recent and past press releases. As obesity and type...